SCHEDULE: Vivo Funds Disclose 5.1% Stake in Compass Therapeutics

Vivo Opportunity Fund Holdings and its affiliates have disclosed a 5.1% passive beneficial ownership stake in Compass Therapeutics, Inc.

Summary

• Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, reported beneficial ownership of 8,995,979 shares of Compass Therapeutics, Inc. common stock.
• This represents a 5.1% stake in the company, based on 177,862,102 shares outstanding as of October 30, 2025.
• Vivo Opportunity Cayman Fund, L.P. and its general partner, Vivo Opportunity Cayman, LLC, also reported beneficial ownership of 549,487 shares, representing 0.3% of the class.
• The filing indicates a passive investment, stating the securities were not acquired to change or influence control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a 5.1% passive stake by a reputable investment fund like Vivo Opportunity Fund Holdings, L.P. suggests a positive outlook on Compass Therapeutics, Inc.'s value proposition and future growth potential.

Positives

• A significant institutional investor, Vivo Opportunity Fund Holdings, L.P., has taken a 5.1% stake in Compass Therapeutics, Inc., indicating confidence in the company's prospects.
• The investment is stated to be passive, suggesting the fund is not seeking to influence management or control, which can be seen as a stable long-term holding.

Risks

• The filing itself does not detail risks related to Compass Therapeutics, Inc.'s operations or financial health. It only states the reporting persons' intent is not to influence control.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Compass Therapeutics, Inc.'s future operations or financial performance.

Management Comments

• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

This filing indicates an institutional investment in a biotechnology company, a common occurrence as funds seek exposure to growth sectors. The passive nature of the investment suggests a belief in the company's existing strategy and potential without requiring active management intervention.

Comparison to Industry Standards

• Not applicable, as this filing is a disclosure of beneficial ownership by an investment fund, not a report on operational or financial results that can be benchmarked against industry peers or projects.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor taking a passive stake may instill confidence and potentially attract further investment, positively impacting share price.

Next Steps

• The filing does not specify any future actions, events, or milestones for Compass Therapeutics, Inc. or the reporting persons beyond the standard regulatory disclosure.

Key Dates

Recommendation

The disclosure of a significant passive stake by Vivo Opportunity Fund Holdings, L.P. in Compass Therapeutics, Inc. suggests institutional confidence in the company's long-term value. While this is a positive signal, the filing itself does not provide new operational or financial data to warrant a 'buy' recommendation. It primarily confirms a substantial investor's position, which supports maintaining existing holdings based on the implied validation of the company's trajectory.

Keywords

Compass Therapeutics, Vivo Opportunity Fund Holdings, Vivo Opportunity, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Institutional Investment, Passive Investment